Wegovy and Clopidogrel Interaction: What Patients and Prescribers Need to Know

Does Wegovy interact with clopidogrel?

The Wegovy drug interactions section has two parts: insulin and insulin secretagogues, because of hypoglycemia risk, and oral medicines as a class, because semaglutide delays gastric emptying [1]. Clopidogrel appears in neither.

Section 7.2 of the Wegovy label states that semaglutide causes a delay of gastric emptying and thereby has the potential to affect absorption of oral medicines given at the same time. It advises increased clinical or laboratory monitoring for oral medicines that have a narrow therapeutic index or require clinical monitoring [1]. The same section records the testing: in clinical pharmacology trials with semaglutide 1 mg once-weekly injection, semaglutide did not affect the absorption of orally administered medications [1].

Interaction studies found no clinically significant effect on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin [1]. The exception recorded in the Wegovy label is levothyroxine, whose exposure rose 33% in a drug interaction study with the semaglutide tablet [1].

Injection or tablets?

Wegovy is available as a once-weekly injection and, since its approval on 2025-12-22, as once-daily tablets for adults [4][1]. The Wegovy label gives these tablet instructions:

• Take it on an empty stomach in the morning with up to 4 ounces of plain water [1]
• Swallow it whole; do not split, crush or chew it [1]
• After taking it, wait at least 30 minutes before eating, drinking or taking other oral medications [1]
• If a dose is missed, skip it and take the next one the following day [1]

The injection has no such timing rule. The label says it is given once weekly on the same day each week, at any time of day, with or without meals [1]. Tablet and injection doses in milligrams are not interchangeable [1].

Does semaglutide affect CYP2C19?

Semaglutide has very low potential to inhibit or induce CYP enzymes [1]. Clopidogrel's activation involves CYP2C19 and other CYP enzymes [2], and no CYP-mediated interaction between the two is described in the Wegovy label [1].

How clopidogrel is switched on

Clopidogrel is a prodrug that must be converted in the body before it blocks platelet P2Y12 receptors. In vitro work with expressed human CYP isoforms found that CYP1A2, CYP2B6 and CYP2C19 carry out the first oxidative step to 2-oxo-clopidogrel, contributing an estimated 35.8%, 19.4% and 44.9% of that step. CYP2B6, CYP2C9, CYP2C19 and CYP3A4 contribute 32.9%, 6.76%, 20.6% and 39.8% of active-metabolite formation [2]. CYP2C19 contributes substantially to both oxidative steps, and CYP3A4 contributes substantially to the second [2].

CYP2C19 genotype and clopidogrel response

The 2022 CPIC guideline states that CYP2C19 intermediate and poor metabolizers who receive clopidogrel have reduced platelet inhibition and a higher risk of major adverse cardiovascular and cerebrovascular events. The update increased the strength of the recommendation for intermediate metabolizers [3].

TAILOR-PCI tested whether acting on genotype improves outcomes. The trial randomized 5,302 patients undergoing PCI to genotype-guided therapy, with ticagrelor for CYP2C19 loss-of-function carriers and clopidogrel for noncarriers, or to conventional clopidogrel [5]. Among carriers, the primary end point occurred in 4.0% with genotype-guided therapy versus 5.9% at 12 months (HR 0.66, 95% CI 0.43 to 1.02, P=0.06), a difference that was not statistically significant [5].

Omeprazole, a better-known clopidogrel interaction

The Plavix label advises avoiding omeprazole and esomeprazole with clopidogrel. Concerns that proton pump inhibitors blunt clopidogrel's effect prompted the COGENT trial, which randomized 3,873 patients with an indication for dual antiplatelet therapy to clopidogrel plus omeprazole or clopidogrel plus placebo, in addition to aspirin [6]. Gastrointestinal events occurred in 1.1% on omeprazole versus 2.9% on placebo at 180 days (HR 0.34, 95% CI 0.18 to 0.63). Cardiovascular events occurred in 4.9% versus 5.7% among 3,761 analyzed patients (HR 0.99, 95% CI 0.68 to 1.44) [6]. The trial was terminated early when the sponsor lost financing [6]. On the Wegovy side, omeprazole did not change semaglutide levels in interaction testing [1].

Where the two drugs overlap in use

Wegovy injection and tablets are both indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [1]. In SELECT, 17,604 adults aged 45 or older with established cardiovascular disease, a BMI of 27 or more and no diabetes were randomized to semaglutide 2.4 mg or placebo. Cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 6.5% versus 8.0% (HR 0.80, 95% CI 0.72 to 0.90) over a mean follow-up of 39.8 months [7].